Unknown statusInterventionalPhase 4Updated Oct 26, 2022
Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis | NCT01344083 | Trialant
Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis
ClinicalTrials.gov ID
NCT01344083
Lead Sponsor
Laboratoires TheaINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
60Estimated
Last Update Posted
Apr 12, 2012Estimated
Start Date
Apr 2011
Primary Completion Date
Feb 2012Actual
Completion Date
Feb 2012Actual
Brief Summary
The aim of this study is to compare the efficacy and the safety of T1210 versus Olopatadine eye drops in the topical treatment of seasonal allergic conjunctivitis.